Oncology Institute Inc

Oncology Institute Inc has a market price of $4.04 per share, resulting in a market capitalization of $403.93 million. The company's price-to-book ratio is 9.78, indicating that the market values the company at a premium to its book value. The enterprise value to EBITDA ratio is negative at -27.39, reflecting the company's current operating losses. The company's profitability metrics are concerning, with a return on equity of -48.16% and a return on assets of -9.72%. These figures are significantly below the industry norms for healthcare providers, which typically exhibit positive returns on equity and assets. The operating income is negative at -$17.97 million, and the net income is also negative at -$19.89 million. Oncology Institute Inc's revenue is concentrated in a single business segment, as disclosed in its financial statements. There is no geographic diversification information provided, but the company's operations are likely centered in the United States, given its listing on the NASDAQ. The lack of geographic diversification could pose a risk if local market conditions deteriorate. The company's growth trajectory is uncertain, with no specific revenue growth projections provided in the available data. However, the operating cash flow is negative at -$15.88 million, and the free cash flow is also negative at -$19.00 million. These cash flow challenges may limit the company's ability to invest in growth opportunities or service its debt obligations. The company faces several risk factors, including liquidity concerns due to negative net cash after subtracting total debt. The debt-to-equity ratio is 2.14, indicating a relatively high level of leverage. The risk assessment also notes a medium liquidity risk, which could impact the company's ability to meet short-term obligations. The dilution risk is currently low, but the company's capital structure and financial performance could change this outlook if additional financing is required. Recent events include analyst estimates that suggest a mean price target of $7.00 and a median price target of $7.50, indicating a potential upside from the current market price. The mean recommendation from analysts is 1.75, which is a positive signal, with one strong-buy and three buy ratings. These analyst sentiments suggest that the market sees potential for the company despite its current financial challenges.